Reviva Pharmaceuticals (NASDAQ:RVPH) Shares Climb 8.3% – Should You Buy?

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH)’s stock price was up 8.3% during trading on Thursday. The company traded as high as $0.5279 and last traded at $0.52. 6,570 shares traded hands during trading, a decline of 98% from the average session volume of 340,033 shares. The stock had previously closed at $0.48.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, July 5th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Reviva Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $53.33.

Reviva Pharmaceuticals Price Performance

The business has a fifty day simple moving average of $0.49 and a 200 day simple moving average of $0.76. The firm has a market cap of $6.82 million, a price-to-earnings ratio of -0.28 and a beta of 0.50.

Reviva Pharmaceuticals (NASDAQ:RVPH) last announced its earnings results on Thursday, August 13th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.19. On average, research analysts anticipate that Reviva Pharmaceuticals Holdings, Inc. will post -2.96 earnings per share for the current fiscal year.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders. The company’s research is based on its proprietary drug-discovery platform, which is designed to identify medicines that act on multiple serotonin and dopamine receptors.

Reviva’s lead product candidate is brilaroxazine, formerly known as RP5063. Brilaroxazine is an investigational multimodal serotonin-dopamine activity modulator being developed for schizophrenia and other neuropsychiatric and inflammatory conditions, including bipolar depression, major depressive disorder, and certain dementia-related psychoses.